These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19901109)

  • 21. Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission.
    Cervetti G; Galimberti S; Carulli G; Petrini M
    Leuk Res; 2005 Sep; 29(9):1097-8. PubMed ID: 16038739
    [No Abstract]   [Full Text] [Related]  

  • 22. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
    Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
    Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence of molecular remission throughout pregnancy in CML after imatinib.
    Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
    Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of the response to imatinib in chronic myeloid leukemia patients--comparison between the FISH, multiplex and RT-PCR methods.
    Raanani P; Ben-Bassat I; Gan S; Trakhtenbrot L; Mark Z; Ashur-Fabian O; Itskovich S; Brok-Simoni F; Rechavi G; Amariglio N; Nagler A
    Eur J Haematol; 2004 Oct; 73(4):243-50. PubMed ID: 15347310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
    Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
    Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
    [No Abstract]   [Full Text] [Related]  

  • 27. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.
    Piccaluga PP; Malagola M; Rondoni M; Arpinati M; Paolini S; Candoni A; Fanin R; Messa E; Pirrotta MT; Lauria F; Visani G; Alberti D; Rancati F; Vinaccia V; Russo D; Saglio G; Baccarani M; Martinelli G
    Haematologica; 2007 Dec; 92(12):1721-2. PubMed ID: 18056005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
    Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
    Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
    Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
    Viniou NA; Vassilakopoulos TP; Giakoumi X; Mantzouranis M; Pangalis GA
    Eur J Haematol; 2004 Jan; 72(1):58-60. PubMed ID: 14962264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
    Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H
    Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
    Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate.
    Chacón M; Roca E; Huertas E; Loria FS; Domenechini E
    J Clin Oncol; 2005 Mar; 23(7):1580-2. PubMed ID: 15735135
    [No Abstract]   [Full Text] [Related]  

  • 36. Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?
    Stagno F; Vigneri P; Di Raimondo F
    Lancet Oncol; 2011 Feb; 12(2):118. PubMed ID: 21277547
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
    Takahari D; Matsunaga T; Fujimi A; Kikuchi T; Seki R; Tanaka I; Takemoto N; Akiyama T; Sato T; Terui T; Kogawa K; Kato J; Kura T; Maeda T; Niitsu Y
    Rinsho Ketsueki; 2002 Oct; 43(10):924-30. PubMed ID: 12462028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
    Abruzzese E; Cantonetti M; Morino L; Orlandi G; Tendas A; Del Principe MI; Masi M; Amadori S; Orlandi A; Anemona L; Campione E
    J Clin Oncol; 2003 Nov; 21(22):4256-8. PubMed ID: 14615464
    [No Abstract]   [Full Text] [Related]  

  • 39. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
    Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
    Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
    Schafhausen P; Dierlamm J; Bokemeyer C; Bruemmendorf TH; Bacher U; Zander AR; Schnittger S; Hochhaus A
    Cancer Genet Cytogenet; 2009 Feb; 189(1):63-7. PubMed ID: 19167615
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.